ArQule-Pfizer deal breaks mold
Article Abstract:
ArQule, a biotechnology company in Medford Mass., signed a technology transfer deal with Pfizer. The deal is worth $117 million and will include the production of exclusive microarray libraries to Pfizer and make it available nonexclusively to Pfizer for another 4.5 years.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Sequenom steps toward drug development
Article Abstract:
Cambridge, UK-based clinical genomics company Gemini Genomics and San Diego, CA-based genetic analysis firm Sequenom have decided to merge their businesses in a stock-for-stock deal worth $238 million.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Chiral drugs viable, despite failure
Article Abstract:
Eli Lilly decided not to re-engineer Sepracor's Prozac, an action that is usually done to maintain a drug patent, which resulted in some financial uncertainty in Sepracor.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The value in breaking up. Drips are drying up
- Abstracts: US lessons for UK telcos. Shop till you drop. The next generation
- Abstracts: The strange death of high-yield stocks. The equity countdown may have begun. Market makers ate my hamster
- Abstracts: Alkit Digital Imaging studio caters to artists. F.J. Westcott Co. celebrates 75 years. Creativity pays off in National Photo Month promotion
- Abstracts: Dealing with technology. Teching stock of the situation. Technology on fire